Effects of inhaled iloprost on right ventricular contractility, right ventriculo-vascular coupling and ventricular interdependence: a randomized placebo-controlled trial in an experimental model of acute pulmonary hypertension.
BACKGROUND
Prostacyclin inhalation is increasingly used to treat acute pulmonary hypertension and right ventricular failure, although its pharmacodynamic properties remain controversial. Prostacyclins not only affect vasomotor tone but may also have cAMP-mediated positive inotropic effects and modulate autonomic nervous system tone. We studied the role of these different mechanisms in the overall haemodynamic effects produced by iloprost inhalation in an experimental model of acute pulmonary hypertension.


METHODS
In this prospective, randomized, placebo-controlled animal study, twenty-six pigs (mean weight 35 +/- 2 kg) were instrumented with biventricular conductance catheters, a pulmonary artery flow probe and a high-fidelity pulmonary artery pressure catheter. The effects of inhaled iloprost (50 microg) were studied in the following groups: animals with acute hypoxia-induced pulmonary hypertension, and healthy animals with and without blockade of the autonomic nervous system.


RESULTS
During pulmonary hypertension, inhalation of iloprost resulted in a 51% increase in cardiac output compared with placebo (5.6 +/- 0.7 versus 3.7 +/- 0.8 l/minute; P = 0.0013), a selective reduction in right ventricular afterload (effective pulmonary arterial elastance: 0.6 +/- 0.3 versus 1.2 +/- 0.5 mmHg/ml; P = 0.0005) and a significant increase in left ventricular end-diastolic volume (91 +/- 12 versus 70 +/- 20 ml; P = 0.006). Interestingly, right ventricular contractility was reduced after iloprost-treatment (slope of preload recruitable stroke work: 2.2 +/- 0.5 versus 3.4 +/- 0.8 mWatt.s/ml; P = 0.0002), whereas ventriculo-vascular coupling remained essentially preserved (ratio of right ventricular end-systolic elastance to effective pulmonary arterial elastance: 0.97 +/- 0.33 versus 1.03 +/- 0.15). In healthy animals, inhaled iloprost had only minimal haemodynamic effects and produced no direct effects on myocardial contractility, even after pharmacological blockade of the autonomic nervous system.


CONCLUSIONS
In animals with acute pulmonary hypertension, inhaled iloprost improved global haemodynamics primarily via selective pulmonary vasodilatation and restoration of left ventricular preload. The reduction in right ventricular afterload is associated with a paradoxical decrease in right ventricular contractility. Our data suggest that this reflects an indirect mechanism by which ventriculo-vascular coupling is maintained at the lowest possible energetic cost. We found no evidence for a direct negative inotropic effect of iloprost.
Rex
Steffen
S
Department of Acute Medical Sciences, Centre for Experimental Anaesthesiology, Emergency and Intensive Care Medicine, Catholic University Leuven, Minderbroedersstraat, 3000 Leuven, Belgium. srex@ukaachen.de
Missant
Carlo
C
Claus
Piet
P
Buhre
Wolfgang
W
Wouters
Patrick F
PF
D000208:Acute Disease; D000280:Administration, Inhalation; D000818:Animals; D002302:Cardiac Output / Q000187:drug effects / Q000502:physiology; D004195:Disease Models, Animal; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000503:physiopathology; D016285:Iloprost / Q000008:administration & dosage*; D011446:Prospective Studies; D034421:Sus scrofa; D016277:Ventricular Function, Left / Q000187:drug effects* / Q000502:physiology; D016278:Ventricular Function, Right / Q000187:drug effects* / Q000502:physiology
D016285:Iloprost
Exp Biol Med (Maywood). 2005 Sep;230(8):507-19
16118400
Chest. 1995 Apr;107(4):1134-45
7705127
Am J Respir Crit Care Med. 2005 Aug 1;172(3):358-63
15879421
Am J Physiol Heart Circ Physiol. 2001 Aug;281(2):H755-63
11454580
Eur J Cardiothorac Surg. 2005 Dec;28(6):882-8
16242948
Chest. 2003 Oct;124(4):1294-304
14555558
Ann N Y Acad Sci. 1990;604:222-36
1977349
Acta Anaesthesiol Scand. 2008 Jan;52(1):65-72
17976224
Intensive Care Med. 2008 Jan;34(1):179-89
17710383
Cardiovasc Res. 1999 Apr;42(1):183-92
10435009
Intensive Care Med. 2003 Sep;29(9):1403-5
12904857
N Engl J Med. 2002 Aug 1;347(5):322-9
12151469
Ann Thorac Surg. 1995 Oct;60(4):1081-6
7574953
Crit Care Med. 2007 Mar;35(3):707-15
17255859
J Appl Physiol (1985). 2004 Mar;96(3):917-22
14578366
Am J Cardiol. 1998 Sep 15;82(6):749-55
9761085
Cardiovasc Res. 1991 Oct;25(10):793-801
1721003
Circulation. 2004 Sep 7;110(10):1308-12
15337703
J Thorac Cardiovasc Surg. 2003 Nov;126(5):1434-41
14666016
Eur J Anaesthesiol. 2006 Oct;23(10):824-31
16953943
J Aerosol Med. 2006 Fall;19(3):353-63
17034310
J Pharmacol Exp Ther. 1988 Mar;244(3):814-9
3075239
Circulation. 2004 Oct 5;110(14):2010-6
15451801
Am J Physiol Heart Circ Physiol. 2001 Dec;281(6):H2697-704
11709439
Circulation. 1997 Mar 18;95(6):1479-86
9118516
Clin Exp Pharmacol Physiol. 1998 Dec;25(12):1032-7
9888002
Am J Physiol Heart Circ Physiol. 2005 Mar;288(3):H1139-46
15513958
Experientia. 1995 Sep 29;51(9-10):941-4
7556575
J Am Coll Cardiol. 2000 Jan;35(1):176-82
10636277
Eur Respir J. 2005 Jan;25(1):81-7
15640327
Circ Res. 1988 Feb;62(2):358-66
3338120
Am J Physiol Heart Circ Physiol. 2005 Mar;288(3):H1157-64
15604134
Am J Physiol. 1981 Jan;240(1):H39-44
7457620
Anesthesiology. 2003 Sep;99(3):745-7
12960562
Eur Heart J. 2008 Jan;29(1):120-7
18065750
Am J Physiol Heart Circ Physiol. 2005 Oct;289(4):H1391-8
15923316
J Biomech. 2003 May;36(5):713-20
12695001
Intensive Care Med. 2003 Sep;29(9):1574-83
12908096
J Cardiovasc Pharmacol. 1985 Jul-Aug;7(4):653-9
2410704
Am J Respir Crit Care Med. 2007 Apr 15;175(8):846-50
17272784
Pharmacol Res Commun. 1983 Sep;15(8):735-49
6138778
Am J Physiol Heart Circ Physiol. 2002 Apr;282(4):H1350-8
11893571
Pharmacol Ther. 2004 May;102(2):139-53
15163595
Cardiovasc Res. 1994 Mar;28(3):303-11
8174149
J Membr Biol. 1990 Feb;113(2):93-107
1690807
Ann Biomed Eng. 1999 Jul-Aug;27(4):480-5
10468232
Crit Care Med. 2007 Jan;35(1):222-9
17095942